Literature DB >> 23292521

Takayasu's arteritis and posterior reversible encephalopathy syndrome: a case-based review.

Carlos Rodrigo Camara-Lemarroy1, Jackeline Grace Lara-Campos, Eduardo Perez-Contreras, René Rodríguez-Gutiérrez, Dionicio Angel Galarza-Delgado.   

Abstract

Autoimmune vasculitides can have diverse neurological manifestations, including posterior reversible encephalopathy syndrome (PRES). Takayasu's arteritis (TA) is an uncommon vasculitis rarely associated with PRES. Common clinical features of TA include hypertension, audible arterial bruits, absence of peripheral pulses, claudication of the extremities, reduced blood pressure in one or both arms, and angiographic abnormalities. PRES has been mostly associated with severe hypertension, endothelial injury, and conditions such as renal disease, immunosuppressive medication use, and rheumatologic diseases. Headaches, seizures, and altered mental status are the main clinical features as well as characteristic findings in magnetic resonance imaging. TA frequently presents with hypertension and is associated with endothelial injury, making this entity an ideal setting for the development of PRES. We report the case of a 17-year-old female who presented to the emergency department with severe hypertension, headache, and seizures. Magnetic resonance imaging findings were suggestive of PRES. She had absent pulses in the right upper extremity, abdominal bruits, and angiographic findings included subclavian and renal artery stenoses. The diagnosis of TA was made, and she responded well to treatment. We found ten additional cases of TA and PRES in the literature. All patients were females under the age of 40, had renovascular hypertension, and presented with headaches and seizures. Current literature relevant to this rare association is presented and discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23292521     DOI: 10.1007/s10067-012-2151-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  47 in total

1.  Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions.

Authors:  S O Casey; R C Sampaio; E Michel; C L Truwit
Journal:  AJNR Am J Neuroradiol       Date:  2000-08       Impact factor: 3.825

Review 2.  Retrospective evaluation of 22 patients with Takayasu's arteritis.

Authors:  Nazife Sule Yasar Bilge; Timuçin Kaşifoğlu; Döndü U Cansu; Cengiz Korkmaz
Journal:  Rheumatol Int       Date:  2011-01-20       Impact factor: 2.631

3.  Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings.

Authors:  Jennifer E Fugate; Daniel O Claassen; Harry J Cloft; David F Kallmes; Osman S Kozak; Alejandro A Rabinstein
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

4.  Anti-endothelial cell antibodies in Takayasu arteritis.

Authors:  J Eichhorn; D Sima; B Thiele; C Lindschau; A Turowski; H Schmidt; W Schneider; H Haller; F C Luft
Journal:  Circulation       Date:  1996-11-15       Impact factor: 29.690

5.  Posterior reversible encephalopathy syndrome (PRES): electroencephalographic findings and seizure patterns.

Authors:  Oliver Kastrup; Markus Gerwig; Markus Frings; Hans-Christoph Diener
Journal:  J Neurol       Date:  2011-12-22       Impact factor: 4.849

Review 6.  Pathogenesis of Takayasu's arteritis: a 2011 update.

Authors:  Laurent Arnaud; Julien Haroche; Alexis Mathian; Guy Gorochov; Zahir Amoura
Journal:  Autoimmun Rev       Date:  2011-08-09       Impact factor: 9.754

Review 7.  Takayasu arteritis in children and adolescents.

Authors:  Juergen Brunner; Brian M Feldman; Pascal N Tyrrell; Jasmin B Kuemmerle-Deschner; Lothar B Zimmerhackl; Ingmar Gassner; Susanne M Benseler
Journal:  Rheumatology (Oxford)       Date:  2010-06-18       Impact factor: 7.580

Review 8.  Posterior reversible encephalopathy syndrome: a review.

Authors:  Steven K Feske
Journal:  Semin Neurol       Date:  2011-05-17       Impact factor: 3.420

9.  [Hypertensive encephalopathy as revealing symptom of Takayasu's arteritis].

Authors:  B Biolsi; D Milhaud; F Raczka; J M Davy; J M Blard; M Pagès
Journal:  Rev Neurol (Paris)       Date:  2003-01       Impact factor: 2.607

10.  Posterior reversible encephalopathy syndrome revealing Takayasu's arteritis.

Authors:  Sunil Karande; Sujit Jagtap; Anagha Joshi
Journal:  Indian J Pediatr       Date:  2008-12-04       Impact factor: 1.967

View more
  6 in total

Review 1.  Eosinophilic granulomatosis with polyangiitis (EGPA) and PRES: a case-based review of literature in ANCA-associated vasculitides.

Authors:  A M Marra; G Barilaro; V Villella; M Granata
Journal:  Rheumatol Int       Date:  2015-04-03       Impact factor: 2.631

2.  Cerebrovascular events in Takayasu arteritis: a multicenter case-controlled study.

Authors:  Priscille Couture; Thibaud Chazal; Charlotte Rosso; Julien Haroche; Anne Léger; Baptiste Hervier; Sandrine Deltour; Zahir Amoura; Fleur Cohen Aubart
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

3.  Posterior Reversible Encephalopathy Syndrome Resolving Within 48 Hours in a Normotensive Patient Who Underwent Thoracic Spine Surgery.

Authors:  Kunal Vakharia; Ioannis Siasios; Vassilios G Dimopoulos; John Pollina
Journal:  J Clin Med Res       Date:  2016-01-26

4.  Posterior reversible encephalopathy syndrome caused by presumed Takayasu arteritis.

Authors:  Ki Wuk Lee; Sang Taek Lee; Heeyeon Cho
Journal:  Korean J Pediatr       Date:  2016-11-30

5.  Posterior Reversible Encephalopathy Syndrome: An Atypical Presentation of Takayasu Arteritis.

Authors:  Abhay Ranjan; Sanaullah Mudassir; Neetu Sinha; Nitin Pandey
Journal:  Ann Indian Acad Neurol       Date:  2022-04-07       Impact factor: 1.714

6.  Severe posterior reversible encephalopathy in pheochromocytoma: importance of susceptibility-weighted MRI.

Authors:  Asli Serter; Alpay Alkan; Ayse Aralasmak; Ercan Kocakoc
Journal:  Korean J Radiol       Date:  2013-08-30       Impact factor: 3.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.